In the last reported quarter, the company’s earnings per share (EPS) of $3.50 surpassed the Zacks Consensus Estimate by 5.7%.

I expect 13 companies to announce their annual increases in the first half of November. Click here for a detailed analysis.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Becton, Dickinson and Company BDX, popularly known as BD, recently launched the new BD Intraosseous (IO) Vascular Access ...

Application error: a client-side exception has occurred (see the browser console for more information).

The global in-vitro diagnostics kit market is experiencing a push of a CAGR of 4.40%, making the market valuation of USD 18.8 ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, today launched the new BD® Intraosseous ...

BD (Becton, Dickinson and Company) , a leading global medical technology company, announced today Health Canada approval of the BD Onclaritytm HPV Assay for human papillomavirus (HPV) testing for the ...

The firm said that the updated approval will improve access to HPV testing by providing a less invasive and less expensive alternative to Pap tests.

With a market cap of $68.8 billion, Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a leading global ...

The global sepsis diagnostics market was valued at US $54 million in the year 2020 and is expected to be worth at US $142 billion by the year 2030. The market is thriving at a compound annual growth ...

CENTRAL TRUST Co lowered its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 43.4% during the 3rd ...